NCT01099670View on ClinicalTrials.gov

Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Fecal Incontinence
Interventions
DRUG

NRL001

Rectal suppository Placebo

DRUG

Placebo

Placebo

Trial Locations (1)

BT2 7BA

Bio-Kinetic Europe Ltd, Belfast

Sponsors

Lead Sponsor

Norgine
All Listed Sponsors
lead

Norgine

INDUSTRY